Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Healthy
Interventions: 3H-Cholesterol; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Spinal Cord Injury
Interventions: fermented foods, Control diet, Sitz Marker Test; Other · Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leukemia, Myeloid, Acute
Interventions: CSL362; Biological
Lead sponsor: CSL Limited; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more

Conditions: Constipation-predominant Irritable Bowel Syndrome
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Impairment, Cognitive, Impairment of Attention, Impairment, Psychomotor
Interventions: Delta-9-THC, Delta-8-THC, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 49 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol; Device · Drug
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 3 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anal Cancer
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions: Magnetic Resonance High Intensity Focused Ultrasound; Device
Lead sponsor: AeRang Kim; Other
Eligibility: Up to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Cincinnati, Ohio

Conditions: Congestive Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
Interventions: Respiratory Sensor measurements; Device
Lead sponsor: Institute of Bioengineering and Bioimaging (IBB); Government
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 24 Years · Female only
Enrollment: 1,387 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Hayward, California • Oakland, California • Richmond, California + 2 more

Conditions: Locally Advanced Cervical Cancer
Interventions: Volrustomig, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 15 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Conditions: Long-Term Memory Decline, Mild Cognitive Impairment
Interventions: LabyrinthVR, Placebo Games, Coherence, Tablet; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 62 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Total Skeletal Irradiation; Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Myocardial Infarction
Interventions: Atorvastatin calcium, Inactive Placebo; Drug
Lead sponsor: The Western Pennsylvania Hospital; Other
Eligibility: 25 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Osteomyelitis
Interventions: Hitachi-Aloka Noblus ultrasound scanner, Magnetic Resonance Imaging (MRI); Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurofibromatosis 1, Neurofibroma, Atypical Neurofibroma, Atypical Neurofibromatosis, Plexiform Neurofibroma, Von Recklinghausen Disease
Interventions: Whole Body MRI; Diagnostic Test
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colorectal Cancer
Interventions: folic acid; Dietary Supplement
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 21 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions: Budesonide, Saline alone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma
Interventions: Talazoparib Oral Capsule; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Multiple Myeloma
Interventions: high dose chemotherapy then autologous hematopoietic cell transplant; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
Interventions: 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation, Mitoxantrone Hydrochloride; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kidney Transplant Rejection
Interventions: TruGraf® Testing; Diagnostic Test
Lead sponsor: Transplant Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Reverse Cholesterol Transport (RCT) Study

Protocol for Women at Increased Risk of Developing Breast Cancer

Fermented Foods and Bowel Health in SCI

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

High Confusion: Cannabis & Driving

Comparison of Nebulizers in ED in Pediatric Asthma Patients

Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Remote Monitoring of High-Risk Patients With Chronic Cardiopulmonary Diseases

Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Wayfinding Intervention in High-Fidelity Long-Term Memory

Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation

To Investigate the Role of Upstream High Dose Statin in STEMI

Detection of Osteomyelitis Using High Resolution Ultrasound

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

BrUOG 390: Neoadjuvant Treatment With Talazoparib

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

TruGraf® Testing in High-Risk Kidney Transplant Recipients